These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2127064)

  • 21. [The role of nitroglycerin in limiting the area of necrosis in myocardial infarction].
    Grodecki J
    Folia Med Cracov; 1989; 30(1-2):31-7. PubMed ID: 2518365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous nitroglycerin-infusion in uncomplicated myocardial infarction?
    Schröder R
    Herz; 1981 Apr; 6(2):84-9. PubMed ID: 6785177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical derangements in ischemic myocardium: the role of carnitine.
    Siliprandi N; Di Lisa F; Toninello A
    G Ital Cardiol; 1984 Oct; 14(10):804-8. PubMed ID: 6240423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnosis and prevention of myocardial reperfusion injury in experimental myocardial infarction].
    Rudnev DV; Pichigin VV; Konorev EA; Konorev LA; Polumiskov VIu
    Kardiologiia; 1988 Dec; 28(12):94-7. PubMed ID: 2468810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of a new structural analog of gamma-butyrobetaine-- 3-(2,2,2-trimethylhydrazine)propionate (THP) on carnitine level, carnitine-dependent fatty acid oxidation and various indices of energy metabolism in the myocardium].
    Simkhovich BZ; Meĭrena DV; Khagi KhB; Kalvin'sh IIa; Lukevits EIa
    Vopr Med Khim; 1986; 32(4):72-6. PubMed ID: 3765501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-ischemic therapy with verapamil. Improving prognosis by secondary prevention after acute myocardial infarct].
    Dotzer F; Gromer H
    Fortschr Med; 1993 May; 111(14):245-8. PubMed ID: 8335304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of verapamil (isoptin) on experimental myocardial infarction in rhesus monkeys.
    Chakravarti RN; Sharma PL; Anand IS; Manga PA; Wahi PL
    Indian J Med Res; 1981 Apr; 73():625-32. PubMed ID: 7262936
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial.
    Tarantini G; Scrutinio D; Bruzzi P; Boni L; Rizzon P; Iliceto S
    Cardiology; 2006; 106(4):215-23. PubMed ID: 16685128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biochemical characteristics of the anti-ischemic action of the new structural analog of gamma-butyrobetaine 3-(2,2,2,-trimethylhydrazine)propionate].
    Simkhovich BZ; Meĭrena DV; Khagi KhB; Kalvin'sh IIa; Lukevits EIa
    Farmakol Toksikol; 1987; 50(2):100-4. PubMed ID: 3582624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Endocrino-metabolic aspects of acute myocardial infarct].
    Orzan F; Fontana V; Brusca A
    Minerva Dietol Gastroenterol; 1981; 27(3):453-66. PubMed ID: 7036001
    [No Abstract]   [Full Text] [Related]  

  • 31. Verapamil in two reperfusion models of myocardial infarction. Temporary protection of severely ischemic myocardium without limitation of ultimate infarct size.
    Reimer KA; Jennings RB
    Lab Invest; 1984 Dec; 51(6):655-66. PubMed ID: 6503220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of L-carnitine biosynthesis and transport by methyl-γ-butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction.
    Liepinsh E; Makrecka-Kuka M; Kuka J; Vilskersts R; Makarova E; Cirule H; Loza E; Lola D; Grinberga S; Pugovics O; Kalvins I; Dambrova M
    Br J Pharmacol; 2015 Mar; 172(5):1319-32. PubMed ID: 25363063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction: safety and biochemical effects.
    Simon K; Szépvölgyi A
    Circulation; 1996 Oct; 94(7):1791. PubMed ID: 8840884
    [No Abstract]   [Full Text] [Related]  

  • 34. The cardioprotective effect of mildronate is diminished after co-treatment with L-carnitine.
    Kuka J; Vilskersts R; Cirule H; Makrecka M; Pugovics O; Kalvinsh I; Dambrova M; Liepinsh E
    J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):215-22. PubMed ID: 21903968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction in myocardial ischemia with nitroglycerin or nitroglycerin plus phenylephrine administered during acute myocardial infarction.
    Borer JS; Redwood DR; Levitt B; Cagin N; Bianchi C; Vallin H; Epstein SE
    N Engl J Med; 1975 Nov; 293(20):1008-12. PubMed ID: 809712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of carnitine on malondialdehyde, taurine and glutathione levels in heart of rats subjected to myocardial stress by isoproterenol.
    Sushamakumari S; Jayadeep A; Kumar JS; Menon VP
    Indian J Exp Biol; 1989 Feb; 27(2):134-7. PubMed ID: 2807405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ursolic acid on cardiac marker enzymes, lipid profile and macroscopic enzyme mapping assay in isoproterenol-induced myocardial ischemic rats.
    Radhiga T; Rajamanickam C; Senthil S; Pugalendi KV
    Food Chem Toxicol; 2012 Nov; 50(11):3971-7. PubMed ID: 22898613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial protection from ischemic preconditioning is not blocked by sub-chronic inhibition of carnitine palmitoyltransferase I.
    Penna C; Mancardi D; Gattullo D; Pagliaro P
    Life Sci; 2005 Sep; 77(16):2004-17. PubMed ID: 15919095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparative effects of obsidan and isoptin on the size of myocardial infarction].
    Agaev MM
    Kardiologiia; 1984 Oct; 24(10):63-6. PubMed ID: 6521185
    [No Abstract]   [Full Text] [Related]  

  • 40. [Experience in using nitroglycerin in the acute period of myocardial infarct].
    Mikhaĭlov AA; Lazutin VK; Zhelnov VV; Simonov VI; Giliarovskiĭ AK
    Kardiologiia; 1981 Dec; 21(12):65-9. PubMed ID: 6799691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.